{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:19:46Z","timestamp":1790518786276,"version":"4.1.0"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"R\u00e9gion Occitanie \/ University of Toulouse","award":["PhD fellowship 2017-2020"],"award-info":[{"award-number":["PhD fellowship 2017-2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Dendrimers are nanosized, arborescent macromolecules synthesized in a stepwise fashion with attractive degrees of functionality and structure definition. This is one of the reasons why they are widely used for biomedical applications. Previously, we have shown that a poly(phosphorhydrazone) (PPH) dendrimer capped with anionic azabisphosphonate groups (so-called ABP dendrimer) has immuno-modulatory and anti-inflammatory properties towards human immune cells in vitro. Thereafter, we have shown that the ABP dendrimer has a promising therapeutic efficacy to treat models of acute and chronic inflammatory disorders in animal models. In these models, the active pharmaceutical ingredient was administered systematically (intravenous and oral administrations), but also loco-regionally in the vitreous tissue. Herein, we assessed the therapeutic efficacy of the ABP dendrimer in the preclinical mouse model of psoriasis induced by imiquimod. The ABP dendrimer was administered in phosphate-buffered saline solution via either systemic injection or topical application. We show that the topical application enabled the control of both the clinical and histopathological scores, and the control of the infiltration of macrophages in the skin of treated mice.<\/jats:p>","DOI":"10.3390\/biom10060949","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T07:14:19Z","timestamp":1592982859000},"page":"949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2058-8254","authenticated-orcid":false,"given":"Ranime","family":"Jebbawi","sequence":"first","affiliation":[{"name":"INSERM, U1043, CNRS, U5282, Universit\u00e9 de Toulouse, UPS, Centre de Physiopathologie de Toulouse-Purpan, F-31300 Toulouse, France"},{"name":"CNRS, UMR 5623, Universit\u00e9 de Toulouse, UPS, Laboratoire des Interactions Mol\u00e9culaires et R\u00e9activit\u00e9 Chimique et Photochimique, IMRCP, 118 route de Narbonne, CEDEX 9, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelouahd","family":"Oukhrib","sequence":"additional","affiliation":[{"name":"CNRS, UPR 8241, Laboratoire de Chimie de Coordination, 205 route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France"},{"name":"LCC-CNRS, Universit\u00e9 de Toulouse, CNRS, 31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-6488","authenticated-orcid":false,"given":"Emily","family":"Clement","sequence":"additional","affiliation":[{"name":"INSERM, U1043, CNRS, U5282, Universit\u00e9 de Toulouse, UPS, Centre de Physiopathologie de Toulouse-Purpan, F-31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-448X","authenticated-orcid":false,"given":"Muriel","family":"Blanzat","sequence":"additional","affiliation":[{"name":"CNRS, UMR 5623, Universit\u00e9 de Toulouse, UPS, Laboratoire des Interactions Mol\u00e9culaires et R\u00e9activit\u00e9 Chimique et Photochimique, IMRCP, 118 route de Narbonne, CEDEX 9, F-31062 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric-Olivier","family":"Turrin","sequence":"additional","affiliation":[{"name":"CNRS, UPR 8241, Laboratoire de Chimie de Coordination, 205 route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France"},{"name":"LCC-CNRS, Universit\u00e9 de Toulouse, CNRS, 31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-3578","authenticated-orcid":false,"given":"Anne-Marie","family":"Caminade","sequence":"additional","affiliation":[{"name":"CNRS, UPR 8241, Laboratoire de Chimie de Coordination, 205 route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France"},{"name":"LCC-CNRS, Universit\u00e9 de Toulouse, CNRS, 31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lacoste","sequence":"additional","affiliation":[{"name":"Imavita S.A.S., Canal Biotech 1, 3 rue des Satellites, Parc Technologique du Canal, F-31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-0689","authenticated-orcid":false,"given":"S\u00e9verine","family":"Fruchon","sequence":"additional","affiliation":[{"name":"INSERM, U1043, CNRS, U5282, Universit\u00e9 de Toulouse, UPS, Centre de Physiopathologie de Toulouse-Purpan, F-31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-8531","authenticated-orcid":false,"given":"R\u00e9my","family":"Poupot","sequence":"additional","affiliation":[{"name":"INSERM, U1043, CNRS, U5282, Universit\u00e9 de Toulouse, UPS, Centre de Physiopathologie de Toulouse-Purpan, F-31300 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"ref_1","unstructured":"The World Health Organization (2016). Global Report on Psoriasis, WHO Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"326","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2016.03.002","article-title":"Shaping the spectrum\u2014From auto-inflammation to auto-immunity","volume":"165","author":"Hedrich","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/labinvest.2012.69","article-title":"Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: Necessity of direct cell-to-cell contact","volume":"92","author":"Martin","year":"2012","journal-title":"Lab. Invest."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/1744666X.2016.1202115","article-title":"Current status and future prospects for biologic treatment of psoriasis","volume":"12","author":"Cline","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.drudis.2016.05.008","article-title":"Immune-competent human skin disease models","volume":"21","author":"Bergers","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrrheum.2010.157","article-title":"Psoriasis: What have we learned from mouse models","volume":"6","author":"Wagner","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Buttler","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00403-012-1272-y","article-title":"Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress","volume":"304","author":"Baek","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Arif, T., and Adil, M. (2016). Nanotechnology - Dermatological perspective. Int. J. Nanomed. Nanosurg., 2.","DOI":"10.16966\/2470-3206.112"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/17425247.2015.982088","article-title":"Nanomedicine-based drug targeting for psoriasis: Potentials and emerging trends in nanoscale pharmacotherapy","volume":"12","author":"Rahman","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/1061186X.2013.771778","article-title":"Hyperbranched dendritic nano-carrier for topical delivery of dithranol","volume":"21","author":"Agrawal","year":"2013","journal-title":"J. Drug Target."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fruchon, S., and Poupot, R. (2017). Pro-inflammatory versus anti-inflammatory effects of dendrimers: The two faces of immuno-modulatory nanoparticles. Nanomaterials, 7.","DOI":"10.3390\/nano7090251"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1100\/tsw.2011.129","article-title":"Anti-inflammatory properties of dendrimers per se","volume":"11","author":"Hayder","year":"2011","journal-title":"Sci. World J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"81ra35","DOI":"10.1126\/scitranslmed.3002212","article-title":"A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis","volume":"3","author":"Hayder","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.biomac.5b00643","article-title":"Phosphorus-based dendrimer ABP treats neuroinflammation by promoting IL-10-producing CD4+ T cells","volume":"16","author":"Hayder","year":"2015","journal-title":"Biomacromolecules"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.3390\/molecules18089305","article-title":"An azabisphosphonate-capped poly(phosphorhydrazone) dendrimer for the treatment of endotoxin-induced uveitis","volume":"18","author":"Fruchon","year":"2013","journal-title":"Molecules"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fruchon, S., and Poupot, R. (2018). The ABP dendrimer, a drug-candidate against inflammatory diseases that triggers the activation of interleukin-10 producing immune cells. Molecules, 23.","DOI":"10.3390\/molecules23061272"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1189\/jlb.0608371","article-title":"Anti-inflammatory and immuno-suppressive activation of human monocytes by a bio-active dendrimer","volume":"85","author":"Fruchon","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar4546","article-title":"Modulation of pro-inflammatory activation of monocytes and dendritic cells by aza-bis-phosphonate dendrimer as an experimental therapeutic agent","volume":"16","author":"Fruchon","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1479-5876-7-82","article-title":"Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy","volume":"7","author":"Portevin","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.nano.2016.07.009","article-title":"Poly(phosphorhydrazone) dendrimers: Yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against Multiple Myeloma","volume":"12","author":"Poupot","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.tetlet.2009.02.127","article-title":"Efficient synthesis of phosphorus-containing dendrimers capped with isosteric functions of amino-bis(methylene) phosphonic acids","volume":"50","author":"Rolland","year":"2009","journal-title":"Tetrahedron Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17672","DOI":"10.1039\/C5NR03884G","article-title":"Interaction studies reveal specific recognition of an anti-inflammatory polyphosphorhydrazone dendrimer by human monocytes","volume":"7","author":"Ledall","year":"2015","journal-title":"Nanoscale"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.1038\/ncomms8722","article-title":"The key role of the scaffold on the efficiency of dendrimer nanodrugs","volume":"6","author":"Caminade","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1021\/acs.biomac.7b01398","article-title":"Three-dimensional directionality is a pivotal structural feature for the bioactivity of azabisphosphonate-capped poly(phosphorhydrazone) nanodrug dendrimers","volume":"19","author":"Hayder","year":"2018","journal-title":"Biomacromolecules"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1096\/fj.06-5742com","article-title":"Design of phosphorylated dendritic architectures to promote human monocyte activation","volume":"20","author":"Poupot","year":"2006","journal-title":"FASEB J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fruchon, S., Bellard, E., Beton, N., Goursat, C., Oukhrib, A., Caminade, A.M., Blanzat, M., Turrin, C.O., Golzio, M., and Poupot, R. (2019). Biodistribution and biosafety of a poly(phosphorhydrazone) dendrimer, an anti-inflammatory drug candidate. Biomolecules, 9.","DOI":"10.3390\/biom9090475"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1084\/jem.20042307","article-title":"The macrophage F4\/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in periphery tolerance","volume":"201","author":"Lin","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bbrc.2015.07.033","article-title":"Perspective: Dendrimer drugs for infection and inflammation","volume":"468","author":"Shaunak","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-3659(03)00200-1","article-title":"Dendrimer-mediated transdermal delivery: Enhanced bioavailability of indomethacin","volume":"90","author":"Chauhan","year":"2003","journal-title":"J. Control. Release"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijpharm.2012.01.041","article-title":"Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene \u2013 In vivo study","volume":"426","author":"Borowska","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e01343","DOI":"10.1016\/j.heliyon.2019.e01343","article-title":"Dendrimer entrapped microsponge gel of dithranol for effective topical treatment","volume":"5","author":"Tripathi","year":"2019","journal-title":"Heliyon"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tox.2017.06.008","article-title":"Quantitative structure-skin permeability relationships","volume":"387","author":"Tsakovska","year":"2017","journal-title":"Toxicology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/jps.21603","article-title":"Poly(amidoamine) dendrimers as skin penetration enhancers: Influence of charge, generation, and concentration","volume":"98","author":"Venuganti","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1773-2247(14)50104-9","article-title":"Modulating topical drug delivery via skin pre-treatment with low-generation poly(amidoamine) dendrimers","volume":"24","author":"Guo","year":"2014","journal-title":"J. Drug Del. Sci. Tech."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00741846","article-title":"\u201cKeratolytic\u201d effect of salicylic acid","volume":"257","author":"Huber","year":"1977","journal-title":"Arch. Dermatol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1007\/s11095-011-0455-0","article-title":"Structure-skin permeability relationship of dendrimers","volume":"28","author":"Venuganti","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/17435390.2014.940406","article-title":"Repeated intravenous injections in non-human primates demonstrate preclinical safety of an anti-inflammatory phosphorus-based dendrimer","volume":"9","author":"Fruchon","year":"2015","journal-title":"Nanotoxicology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:56Z","timestamp":1760175716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/6\/949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["biom10060949"],"URL":"https:\/\/doi.org\/10.3390\/biom10060949","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}